The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib

The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib

The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Society of Clinical Oncology and dermatovenerologists. PIK3CA mutation is a poor prognostic factor for HR+ HER2- metastatic br...

Full description

Bibliographic Details
Main Authors:	Irena L. Shlivko, Oxana E. Garanina, Elena V. Artamonova, Inna P. Ganshina, Liudmila G. Zhukova, Irina A. Koroleva, Anna V. Michenko, Tatiana Yu. Semiglazova, Daria A. Filonenko
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2021-12-01
Series:	Современная онкология
Subjects:	consensus rash alpelisib breast cancer pik3ca mutation
Online Access:	https://modernonco.orscience.ru/1815-1434/article/viewFile/100019/73503

Similar Items

The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
by: Natalya V. Mazurina, et al.
Published: (2021-02-01)

Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice
by: D. A. Filonenko, et al.
Published: (2021-12-01)

Alpelisib therapy: from theory to practice
by: E. V. Lubennikova, et al.
Published: (2022-06-01)

Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report
by: Maayan Geller Hinich, et al.
Published: (2023-10-01)

A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
by: Sara Donzelli, et al.
Published: (2022-07-01)

Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience
by: Sabah Alaklabi, et al.
Published: (2022-10-01)

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells
by: Slavomir Krajnak, et al.
Published: (2023-01-01)

PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib
by: Angelica Pagliazzi, et al.
Published: (2021-09-01)

Case Report: Alpelisib-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Rare Manifestation of a Common Side Effect
by: Umair Majeed, et al.
Published: (2021-08-01)

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trialResearch in context
by: Antonio Llombart-Cussac, et al.
Published: (2024-05-01)

Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines
by: Jiah Yeom, et al.
Published: (2023-11-01)

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
by: Maria Letizia Cataldo, et al.
Published: (2023-07-01)

Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
by: Tsvetalina Tankova, et al.
Published: (2022-03-01)

The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
by: Irina V. Poddubnaya, et al.
Published: (2021-02-01)

Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature
by: Maritza Carrillo, MD, et al.
Published: (2021-03-01)

Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
by: Ari Raphael, et al.
Published: (2022-09-01)

Periorbital edema associated with alpelisib
by: Elizabeth A. Dao, et al.
Published: (2022-01-01)

Alpelisib-induced thyroiditis in a patient with metastatic breast cancer: Is routine monitoring of thyroid function required?
by: Calvin R Flynn, et al.
Published: (2023-03-01)

Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
by: Mohamed E. Shaker, et al.
Published: (2023-08-01)

Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences
by: Yuhao Ye, et al.
Published: (2023-03-01)

Pulmonary Vein Stenosis Associated with Germline <i>PIK3CA</i> Mutation
by: Delphine Yung, et al.
Published: (2022-05-01)

Corrigendum: Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
by: Mohamed E. Shaker, et al.
Published: (2023-09-01)

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
by: Yun Li, et al.
Published: (2024-03-01)

Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer – A Real-Life Experience
by: Percik R, et al.
Published: (2023-05-01)

Bilateral Panuveitis and Exudative Retinal Detachments Associated with Alpelisib
by: Yu Jeat Chong, et al.
Published: (2022-08-01)

Butterfly rash with periodontitis: A diagnostic dilemma
by: Manvi Aggarwal, et al.
Published: (2012-01-01)

The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
by: Anna Passarelli, et al.
Published: (2023-01-01)

Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population
by: Qingfeng Huang, et al.
Published: (2022-07-01)

Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer
by: Deborah L. Toppmeyer, et al.
Published: (2020-09-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

Bioanalysis of alpelisib using liquid chromatography–tandem mass spectrometry and application to pharmacokinetic study
by: Seop Lee, et al.
Published: (2022-08-01)

Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
by: Chang DY, et al.
Published: (2021-03-01)

P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer
by: Hao Chen, et al.
Published: (2023-09-01)

Antipsychotics and rashes
by: Jessica Lin
Published: (2018-11-01)

A Rare Pathological Phenotype of Endometrioid Serous and Clear-Cell Ovarian Cancer with PIK3CA Mutations in Relation to The Excellent Response of Alpelisib
by: Ertugrul Bayram, et al.
Published: (2023-08-01)

Case report: Alpelisib-induced Stevens–Johnson syndrome
by: Christine Jane Kurian, et al.
Published: (2022-09-01)

Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer
by: Huan Yang, et al.
Published: (2024-02-01)

A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations
by: Guillaume Canaud, et al.
Published: (2021-07-01)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer
by: Olga Martínez-Sáez, et al.
Published: (2020-05-01)

A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor
by: Maria A. Pantaleo, et al.
Published: (2022-05-01)